Innocan Pharma Corporation: Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

A 4-year-old intact male border collie dog with a body weight of 22 kg was suffering from refractory idiopathic (drug-resistant) epilepsyThe dog was frequently hospitalized to stop seizure clusters Following

Related Keywords

Jerusalem ,Israel General ,Israel ,Herzliya ,Tel Aviv ,Canada ,Hebrew University ,Yerushalayim ,Canadian ,Iris Bincovich ,Chezy Barenholz ,Innocan Pharma ,Development Company Yissum ,Company Or Innocan ,Innocan Pharma Corporation ,Liposome Research Department ,Market Research ,Innocan Pharma Ltd ,Hebrew University Of Jerusalem ,Alberta Newsfile Corp ,Tel Aviv University ,Yissum Research ,Liposome Platform ,Pharma Corporation ,Allied Market Research ,Global Anti Epilepsy Drugs Market Size ,Market Watch ,Pharma Ltd ,Development Company ,Professor Chezy Barenholz ,Professor Barenholz ,Innocan ,Dharma ,Corporation ,Reports ,Another ,Uccessful ,Result ,Rom ,Linical ,Study ,Suffering ,Refractory ,Drug ,Resistant ,Epilepsy ,Following ,Treatment ,